Wide Ranks

ENLV

Enlivex Therapeutics Ltd.

1.14

Top Statistics
Market Cap 24 M Forward PE -1.97 Revenue Growth 0.00 %
Current Ratio 10.06 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.0730 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 25 M Total Cash Per Share 1.24 Total Debt 835000
Total Debt To Equity 2.92 Current Ratio 10.06 Book Value Per Share 1.37
All Measures
Short Ratio 56.00 % Message Board Id finmb_84011067 Fax 972 2 670 8070
Shares Short Prior Month 100865 Return On Equity -0.6117 City Ness Ziona
Uuid b74cb9f5-e16c-38f4-8a35-7f19c807ad7d Previous Close 1.07 First Trade Date Epoch Utc 1 B
Book Value 1.37 Beta 1.10 Total Debt 835000
Volume 258669 Price To Book 0.8333 Last Split Date 1 B
Fifty Two Week Low 0.8100 Total Cash Per Share 1.24 Shares Short Previous Month Date 1 B
Target Median Price 9.50 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Target Mean Price 9.50 Net Income To Common -22294000
Short Percent Of Float 0.0049 Implied Shares Outstanding 21 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 238780 Average Volume10days 238780
Total Cash 25 M Next Fiscal Year End 1 B Held Percent Insiders 0.0574
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.07 Target Low Price 6.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.37 Open 1.15 Free Cashflow -11977375
Dividend Yield 0.00 % Return On Assets -0.2746 Time Zone Short Name EST
Trailing Eps -1.18 Day Low 1.10 Address1 14 Einstein Street
Shares Outstanding 21 M Price Hint 4 Target High Price 13.00
Website https://www.enlivex.com 52 Week Change -0.3804 Average Volume 154059
Forward Eps -0.5800 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 957.40 % Last Split Factor 1:8 Regular Market Day High 1.16
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 2.92
Fifty Two Week High 4.59 Day High 1.16 Shares Short 99233
Regular Market Open 1.15 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0046 Operating Cashflow -17023000
Currency USD Time Zone Full Name America/New_York Market Cap 24 M
Is_nasdaq_100 False Zip 7403618 Quote Type EQUITY
Industry Biotechnology Long Name Enlivex Therapeutics Ltd. Regular Market Day Low 1.10
Held Percent Institutions 0.1881 Current Price 1.14 Enterprise To Ebitda 0.0730
Financial Currency USD Current Ratio 10.06 Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country Israel Float Shares 15 M
Two Hundred Day Average 1.83 Enterprise Value -1300024 Forward PE -1.97
Regular Market Volume 258669 Ebitda -17893000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Enlivex Therapeutics Ltd.

, together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis.

The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.

Enlivex Therapeutics Ltd.

is headquartered in Ness Ziona, Israel.